乙酰胆碱受体抗体作为重症肌无力的诊断检测：153例确诊病例及2967次诊断检测的结果
Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.
作者信息
Vincent A, Newsom-Davis J
出版信息
J Neurol Neurosurg Psychiatry. 1985 Dec;48(12):1246-52. doi: 10.1136/jnnp.48.12.1246.
Abstract
Anti-acetylcholine receptor (AChR) antibody was undetectable in 26/153 (17%) sera from myasthenia gravis patients assayed by standard RIA using human acetylcholine receptor. Eight of these were found to be positive with a modified protocol using a mixture of normal and denervated AChR, reducing the proportion of "negative" sera to 12%. Many of these were from patients with a short history; two such patients later developed low positive values. Anti-AChR without clinical evidence of myasthenia was found in one of three monozygotic twins of myasthenia gravis patients, and in one of thirty other first degree relatives of a further 17 patients. Anti-AChR is a valuable and highly specific diagnostic test which, with the assay used here, is positive in about 88% of patients with clinical features of myasthenia gravis.
摘要
采用使用人乙酰胆碱受体的标准放射免疫分析法（RIA）检测重症肌无力患者的血清，在153例患者中有26例（17%）未检测到抗乙酰胆碱受体（AChR）抗体。其中8例采用改良方案检测呈阳性，该改良方案使用正常和失神经支配的AChR混合物，使“阴性”血清比例降至12%。这些患者中许多病程较短；其中两名患者后来出现低阳性值。在重症肌无力患者的三对单卵双胞胎中的一对，以及另外17例患者的30名其他一级亲属中的1名中，发现了无重症肌无力临床证据的抗AChR。抗AChR是一项有价值且高度特异的诊断检测，采用此处所用的检测方法，约88%具有重症肌无力临床特征的患者呈阳性。
相似文献
1
Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.乙酰胆碱受体抗体作为重症肌无力的诊断检测：153例确诊病例及2967次诊断检测的结果
J Neurol Neurosurg Psychiatry. 1985 Dec;48(12):1246-52. doi: 10.1136/jnnp.48.12.1246.
2
Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis.乙酰胆碱受体抗体与重症肌无力患者胸腺切除术后的临床反应
Neurology. 1983 Oct;33(10):1276-82. doi: 10.1212/wnl.33.10.1276.
3
Comparison of antigenic sources for acetylcholine receptor antibody assays in myasthenia gravis.重症肌无力中乙酰胆碱受体抗体检测抗原来源的比较。
Ann Neurol. 1980 Jul;8(1):61-6. doi: 10.1002/ana.410080109.
4
A sensitive rosetting assay for detection of acetylcholine receptor antibodies using BC3H-1 cells: positive results in 'antibody-negative' myasthenia gravis.一种使用BC3H-1细胞检测乙酰胆碱受体抗体的敏感玫瑰花结试验：“抗体阴性”重症肌无力患者的阳性结果
J Neuroimmunol. 1990 Jun;28(1):83-93. doi: 10.1016/0165-5728(90)90043-m.
5
Anti-acetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations.重症肌无力患者胸腺切除术后抗乙酰胆碱受体抗体水平降低。临床相关性。
J Autoimmun. 1991 Apr;4(2):197-211. doi: 10.1016/0896-8411(91)90018-8.
6
[Value of acetylcholine receptor antibodies in myasthenia gravis].[乙酰胆碱受体抗体在重症肌无力中的价值]
Wien Med Wochenschr. 1986 Jul 15;136(13):329-32.
7
Antibody to acetylcholine receptor in canine and human myasthenia gravis: differential cross-reactivity with human and rabbit receptor.犬和人类重症肌无力中抗乙酰胆碱受体抗体：与人及兔受体的交叉反应差异
Neurology. 1979 Jul;29(7):1065-8. doi: 10.1212/wnl.29.7.1065.
8
Myasthenia gravis: antibodies to acetylcholine receptor with human and rat antigens.重症肌无力：含人类和大鼠抗原的乙酰胆碱受体抗体。
Neurology. 1980 May;30(5):543-6. doi: 10.1212/wnl.30.5.543.
9
Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.乙酰胆碱受体抗体检测在眼肌型重症肌无力中的临床应用。
JAMA Neurol. 2015 Oct;72(10):1170-4. doi: 10.1001/jamaneurol.2015.1444.
10
Acetylcholine receptor antibodies in the diagnosis of human and experimental myasthenia gravis.乙酰胆碱受体抗体在人类及实验性重症肌无力诊断中的应用
Muscle Nerve. 1978 Sep-Oct;1(5):427-31. doi: 10.1002/mus.880010518.
引用本文的文献
1
A Case of Pediatric Myasthenia Revealed by Marked Eyelid Ptosis After Using Cyclopentolate Eye Drops.一例使用环喷托酯滴眼液后出现明显眼睑下垂而确诊的小儿肌无力病例。
Cureus. 2025 Mar 3;17(3):e79945. doi: 10.7759/cureus.79945. eCollection 2025 Mar.
2
Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravis.α-胰蛋白酶抑制剂重链 H3 是重症肌无力疾病活动的潜在生物标志物。
Acta Neuropathol. 2024 Jun 18;147(1):102. doi: 10.1007/s00401-024-02754-6.
3
Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis.自身免疫性神经病和重症肌无力常规自身抗体检测方法的实验室间比较。
J Neurol. 2024 Jul;271(7):4119-4130. doi: 10.1007/s00415-024-12317-0. Epub 2024 Apr 5.
4
Real-World experience with efgartigimod in patients with myasthenia gravis.真实世界中依库珠单抗治疗重症肌无力患者的经验。
J Neurol. 2024 Jun;271(6):3462-3470. doi: 10.1007/s00415-024-12293-5. Epub 2024 Mar 25.
5
Protective Effects of Whey Protein Hydrolysate, Treadmill Exercise, and Their Combination against Scopolamine-Induced Cognitive Deficit in Mice.乳清蛋白水解物、跑步机运动及其组合对东莨菪碱诱导的小鼠认知缺陷的保护作用
Foods. 2023 Dec 10;12(24):4428. doi: 10.3390/foods12244428.
6
Residual serum fibrinogen as a universal biomarker for all serotypes of Myasthenia gravis.残余血清纤维蛋白原作为重症肌无力所有血清型的通用生物标志物。
Sci Rep. 2023 Dec 1;13(1):21229. doi: 10.1038/s41598-023-47559-x.
7
Current Biomarker Strategies in Autoimmune Neuromuscular Diseases.自身免疫性神经肌肉疾病的当前生物标志物策略。
Cells. 2023 Oct 15;12(20):2456. doi: 10.3390/cells12202456.
8
Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.免疫疗法在 MuSK 阳性重症肌无力中的应用；一种 IgG4 抗体介导的疾病。
Front Immunol. 2023 Jul 26;14:1212757. doi: 10.3389/fimmu.2023.1212757. eCollection 2023.
9
New and emerging treatments for myasthenia gravis.重症肌无力的新型及新兴治疗方法。
BMJ Med. 2023 Aug 7;2(1):e000241. doi: 10.1136/bmjmed-2022-000241. eCollection 2023.
10
Optimal validation of accuracy in antibody assays and reasonable definition of antibody positive/negative subgroups in neuroimmune diseases: a narrative review.神经免疫疾病中抗体检测准确性的最佳验证及抗体阳性/阴性亚组的合理定义：一项叙述性综述
Ann Transl Med. 2023 Apr 15;11(7):280. doi: 10.21037/atm-21-2384. Epub 2022 Jul 28.
本文引用的文献
1
Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations.重症肌无力中的体液免疫：获得性抗受体抗体的生化特征及临床相关性
Ann Neurol. 1981 Nov;10(5):437-47. doi: 10.1002/ana.410100506.
2
Congenital myasthenia: end-plate acetylcholine receptors and electrophysiology in five cases.先天性肌无力：5例终板乙酰胆碱受体与电生理研究
Muscle Nerve. 1981 Jul-Aug;4(4):306-18. doi: 10.1002/mus.880040407.
3
Myasthenia gravis: antibodies to acetylcholine receptor with human and rat antigens.重症肌无力：含人类和大鼠抗原的乙酰胆碱受体抗体。
Neurology. 1980 May;30(5):543-6. doi: 10.1212/wnl.30.5.543.
4
Antibodies to acetylcholine receptor in patients with thymoma but without myasthenia gravis.胸腺瘤但无重症肌无力患者体内的乙酰胆碱受体抗体
Neurology. 1980 Feb;30(2):201-2. doi: 10.1212/wnl.30.2.201.
5
alpha-Bungarotoxin displacing antibody in myasthenia gravis.重症肌无力中的α-银环蛇毒素置换抗体
J Clin Lab Immunol. 1982 Nov;9(2):113-7.
6
Purification of anti-acetylcholine receptor antibody from patients with myasthenia gravis.
J Immunol Methods. 1982;51(3):371-81. doi: 10.1016/0022-1759(82)90405-7.
7
Acetylcholine receptor antibodies in myasthenia gravis.重症肌无力中的乙酰胆碱受体抗体
Muscle Nerve. 1981 Sep-Oct;4(5):413-9. doi: 10.1002/mus.880040510.
8
Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis.重症肌无力疾病异质性的临床、病理、HLA抗原及免疫学证据
Brain. 1980 Sep;103(3):579-601. doi: 10.1093/brain/103.3.579.
9
Neuromuscular safety margin: genetical, immunological and electrophysiological determinants in relatives of myasthenic patients: a preliminary report.
Ann N Y Acad Sci. 1981;377:606-13. doi: 10.1111/j.1749-6632.1981.tb33761.x.
10
Acetylcholine receptor antibody characteristics in myasthenia gravis. Fractionation of alpha-bungarotoxin binding site antibodies and their relationship to IgG subclass.重症肌无力中乙酰胆碱受体抗体的特征。α-银环蛇毒素结合位点抗体的分离及其与IgG亚类的关系。
J Neuroimmunol. 1983 Aug;5(1):1-9. doi: 10.1016/0165-5728(83)90022-x.
Zotero 插件